Literature DB >> 9673831

Determination of the distribution volume that can be used to calculate the intravenous loading dose.

D R Wada1, D R Drover, H J Lemmens.   

Abstract

An intravenous loading dose is given to rapidly achieve a desired drug concentration in the blood. A loading dose calculated with the volume of distribution (Vd) at steady state will result in high peak concentrations and possibly serious adverse effects. A loading dose based on the central compartment Vd (Vc) followed by a maintenance infusion may also miss the target drug concentration and cause serious adverse effects. The Vd can be viewed as a time-dependent variable that expands from the Vc immediately after injection, to eventually include the steady-state Vd. If the loading dose is calculated from a Vd determined after the time of peak effect (tmax), then the actual concentration will exceed the target concentration at the tmax. If a loading dose is calculated from a Vd before the peak effect occurs, the actual concentration will be insufficient to achieve the target concentration at tmax. A loading dose based on the Vd at the tmax will accurately achieve the concentration at the tmax without unexpected adverse effects. To determine the Vd at peak effect, it is necessary that an effect can be measured, the peak effect can be detected and the plasma concentrations are sampled frequently enough to quantify the plasma concentrations at the tmax. For drugs that attain an ultra-fast effect (1 to 2 minutes), arterial samples need to be measured. If the onset of effect is intermediate or slow, venous blood can be sampled as the arterial and venous concentrations may be similar at the tmax.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9673831     DOI: 10.2165/00003088-199835010-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  24 in total

1.  Time-dependent distribution volume and kinetics of the pharmacodynamic effector site.

Authors:  T K Henthorn; T C Krejcie; C A Shanks; M J Avram
Journal:  J Pharm Sci       Date:  1992-11       Impact factor: 3.534

Review 2.  The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part II).

Authors:  W L Chiou
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

3.  Pharmacokinetic model selection for target controlled infusions of propofol. Assessment of three parameter sets.

Authors:  J F Coetzee; J B Glen; C A Wium; L Boshoff
Journal:  Anesthesiology       Date:  1995-06       Impact factor: 7.892

4.  Predictive accuracy of continuous alfentanil infusion in volunteers: variability of different pharmacokinetic sets.

Authors:  L Barvais; F Cantraine; A D'Hollander; E Coussaert
Journal:  Anesth Analg       Date:  1993-10       Impact factor: 5.108

5.  Optimized blood sampling protocols and sequential design of kinetic experiments.

Authors:  J J DiStefano
Journal:  Am J Physiol       Date:  1981-05

6.  Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application.

Authors:  C F Minto; T W Schnider; S L Shafer
Journal:  Anesthesiology       Date:  1997-01       Impact factor: 7.892

7.  Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development.

Authors:  C F Minto; T W Schnider; T D Egan; E Youngs; H J Lemmens; P L Gambus; V Billard; J F Hoke; K H Moore; D J Hermann; K T Muir; J W Mandema; S L Shafer
Journal:  Anesthesiology       Date:  1997-01       Impact factor: 7.892

8.  Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation.

Authors:  J C Scott; D R Stanski
Journal:  J Pharmacol Exp Ther       Date:  1987-01       Impact factor: 4.030

9.  Alfentanil kinetics in the elderly.

Authors:  H Helmers; A Van Peer; R Woestenborghs; H Noorduin; J Heykants
Journal:  Clin Pharmacol Ther       Date:  1984-08       Impact factor: 6.875

Review 10.  The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part I).

Authors:  W L Chiou
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

View more
  8 in total

Review 1.  [Modern concepts in pharmacokinetics of intravenous anesthetics].

Authors:  T Heidegger; C F Minto; T W Schnider
Journal:  Anaesthesist       Date:  2004-01       Impact factor: 1.041

Review 2.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics.

Authors:  D T Bearden; K A Rodvold
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

Review 4.  Pharmacokinetic Pharmacodynamic Modelling Contributions to Improve Paediatric Anaesthesia Practice.

Authors:  James D Morse; Luis Ignacio Cortinez; Brian J Anderson
Journal:  J Clin Med       Date:  2022-05-26       Impact factor: 4.964

Review 5.  Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone.

Authors:  David R Drover
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Yuki Hanai; Yoshiko Takahashi; Takashi Niwa; Toshihiko Mayumi; Yukihiro Hamada; Toshimi Kimura; Kazuaki Matsumoto; Satoshi Fujii; Yoshio Takesue
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790

7.  Time Varying Apparent Volume of Distribution and Drug Half-Lives Following Intravenous Bolus Injections.

Authors:  Carl A Wesolowski; Michal J Wesolowski; Paul S Babyn; Surajith N Wanasundara
Journal:  PLoS One       Date:  2016-07-12       Impact factor: 3.240

8.  Surfactant Assisted Rapid-Release Liposomal Strategies Enhance the Antitumor Efficiency of Bufalin Derivative and Reduce Cardiotoxicity.

Authors:  Lina Gao; Lei Zhang; Fengjun He; Jing Chen; Meng Zhao; Simin Li; Hao Wu; Yumeng Liu; Yinan Zhang; Qineng Ping; Lihong Hu; Hongzhi Qiao
Journal:  Int J Nanomedicine       Date:  2021-05-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.